Background Since a non-negligible fraction of patients with metastatic melanoma does not
experience long-term disease control, even with immunotherapy and targeted therapy, new …

Purpose To evaluate the pan-immune-inflammation value (PIV) and systemic immune-
inflammation index (SII) in patients with cutaneous melanoma (CM) under immune …

Background: Ipilimumab improves the survival of metastatic melanoma patients. Despite
documented, durable objective responses, a significant number of patients fails to benefit …

Background Clinical responses to ipilimumab are variable in terms of onset, magnitude and
duration. Upfront identification of patients who are more likely or unlikely to benefit from …

Purpose: Characterize tumor burden dynamics during PD-1 inhibitor therapy and investigate
the association with overall survival (OS) in advanced melanoma. Experimental Design: The …

Background Malignant melanoma is an immunogenic skin cancer with an increasing global
incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no …

Introduction: A high proportion of metastatic melanoma patients do not respond to immune
checkpoint inhibitors (ICI), and until now, no validated biomarkers for response and survival …

As diverse therapeutic options are now available for advanced melanoma patients,
predictive markers that may assist treatment decision are needed. A model based on …

Immunotherapy has revolutionized the treatment in metastatic melanoma, but alternative
biomarkers that are economical, simple and reliable still need to be clarified. In this study …

Purpose The purpose of this study was to set up a prognostic model for the identification of
survival predictors specific for melanoma patients treated with ipilimumab. Experimental …